• Benefits and risks of target Hb 10-11.5g/dl
• Outcomes in certain populations with anemia of CKD (non-iron replete, inflammation, transplant)
• Personalized Hb targets and outcome in dialysis populations
• Post transplant anemia


•   Understanding the patient perspective on unmet need in CHB
•   Understanding subpopulations in CHB with greatest need for improved outcomes e.g. those at most risk from HCC
•   Understanding impact of reduced access to care on outcomes in underserved populations with CHB
•   Understanding low diagnosis rates in CHB, impact to outcomes and opportunities to improve
•   Understanding the impact of CHB on patient-important outcomes, including functional cure
•   Measuring value of functional cure versus viral suppression in CHB
•   Understanding the biological mechanisms that lead to functional cure, including heterogeneity of virological and immunological effects
•   Societal and cultural impacts on treatment decision making
•   HBsAg qualitative versus quantitative assessment in CHB – role in improving CHB management and outcomes


• Implementing/assessing care pathways that deploy quality-of-life measures and/or symptom assessments into routine clinical care of patients with PBC
• Investigating the mechanism of disease of cholestatic pruritus: basic and clinical research into the interplay of biomarkers, for example bile acids and LPA/autotaxin
• Improving the capture of patient reported outcomes in national/international PBC registries, to increase the understanding of the severity, and quality of life impact, of symptoms of PBC